ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

BioAge Labs to Present Data on Novel Brain-Penetrant NLRP3 Inhibitors for Treatment of Neurodegeneration and Brain Aging at Upcoming Conferences

Family of NLRP3 inhibitors is differentiated by novel structure, central nervous system penetration, and potential for improved safety and efficacy

BioAge Labs, Inc. (“BioAge”), a privately held clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that it will present updates on its NLRP3 inhibitor program [link] at two upcoming conferences in the United States, Neurodegeneration Targets and the Inflammasome Therapeutics Summit, and at the BIO-Europe 2022 conference in Leipzig, Germany. BioAge is developing its novel, proprietary class of NLRP3 inhibitors, which have distinct structural and biological properties and include molecules that penetrate the blood–brain barrier, for neurodegenerative and neurosensory disorders associated with aging.

“Our family of potent, structurally differentiated NLRP3 inhibitors demonstrates BioAge’s capability to discover novel compounds for promising targets emerging from our discovery platform,” said BioAge CEO and co-founder Kristen Fortney, PhD. “I am excited about the potential of these drugs to treat diseases driven by brain aging, and our team is looking forward to the opportunity to share recent data from this program at multiple important scientific gatherings.”

At the inaugural Neurodegeneration Targets meeting hosted by Cambridge Healthtech Institute [link], Rusty Montgomery, PhD, Vice President, Biology, will deliver a talk titled “Identification of a Novel Class of Highly Potent, CNS-Penetrant NLRP3-Specific Inhibitors with Excellent Drug-Like Physical Features” in Boston, MA on Oct. 20, 2022. Kevin Willhelmsen, PhD, Associate Director of Immunology, will present on the same topic at the Inflammasome Therapeutics Summit [link] in Boston on Nov. 29, 2022.

In addition, at BIO-Europe [link], Peng Leong, PhD, MBA, Chief Business Officer and Head of Brain Aging at BioAge, will speak on a panel titled “Immuno-inflammation: A Gateway to Therapeutic Areas and New Partners” on Oct. 24, 2022. He will be joined by panelists Vishal Sahni, Director, Corporate Business Development and Strategy at H. Lundbeck A/S; Duncan Emmerton, Executive Director, Pharma Intelligence; and Andrew Mackie, Chief Business Officer, Imcyse.

“The BioAge target discovery platform revealed that NLRP3 activity is correlated with mortality and cognitive decline,” Leong said, “Inhibition of NLRP3 and other mediators of chronic inflammation identified by our platform has the potential to prevent multiple age-related disorders driven by pathologic inflammation.”

Leong will be available at BIO-Europe for potential partnership discussions. Attendees can send meeting requests to BioAge via the contact information in this release.

About BioAge Labs, Inc.

BioAge is a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records to map out the key molecular pathways that impact healthy human aging. By targeting the mechanisms of aging with a large and mechanistically diverse portfolio of drugs, BioAge is unlocking opportunities to treat or even prevent age-related disease in entirely new ways. BioAge currently has multiple clinical-stage programs in its growing portfolio targeting muscle, immune, and brain aging. To date, BioAge has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others. For additional information about BioAge, visit the company’s website at https://www.bioagelabs.com.

BioAge is developing its novel, proprietary class of brain-penetrant NLRP3 inhibitors for neurodegenerative and neurosensory disorders associated with aging. The company will present updates on the NLRP3 program at upcoming conferences.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.